登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

2008 Top 20 Pharmaceutical/Biopharmaceutical Companies Report   

2009-01-31 13:43:09|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

2008 Top 20 Pharmaceutical Companies Report



The weak U.S. dollar played a strong role in this year’s Top 20 Pharma Report. Several overseas players look a lot better than they should, thanks to my insistence on converting all results to dollars. In local currencies, many foreign and domestic players were barely able to eke out growth in 2007. Several companies still managed to post solid gains during the year, but even they were haunted by the specter of patent expirations to come.

It was a tough year at many of these companies, with layoffs reaching the tens of thousands. New leadership teams, with chief executives not much older than your humble editor, have inherited truly untenable situations.

—Gil Y. Roth, Editor

Top 20 Pharmaceutical Companies
01 Pfizer $44,424
02 GlaxoSmithKline $38,501
03 Sanofi-Aventis $38,452
04 AstraZeneca $28,713
05 Merck $26,532
06 Novartis $25,477
07 Johnson & Johnson $24,866
08 Roche $21,998
09 Eli Lilly & Co. $17,638
10 Wyeth $17,179
11 Bristol-Myers Squibb $15,622
12 Abbott Laboratories $14,632
13 Schering-Plough $12,773
14 Bayer Schering $12,294
15 Boehringer Ingelheim $11,103
16 Takeda $10,626
17 Astellas* $8,530
18 Daiichi-Sankyo* $7,382
19 Eisai* $6,250
20 UCB Group* $4,370

Based on 2007 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company's page.

* PDF profiles only available for companies 17-20

Contributors


Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Abbott Laboratories, by Kristin Brooks.


2008 Top 10 Biopharmaceutical Companies Report



After years of producing this report, I’ve finally settled on definitive criteria for the Top Biopharma ranks! After consulting with Ronald A. Rader, president of the Biotechnology Information Institute, I decided that a Top Biopharma company is one that makes more than 40%?of its drug revenues by selling biologic products, including biotherapeutics, vaccines and other proteins. No royalty-based companies allowed!?(Sorry, ImClone.)

Unfortunately, this new criteria resulted in my only finding nine qualifying companies. I eventually settled on Elan for the tenth spot, since the company co-markets Tysabri with Biogen Idec. If you can think of other companies that qualify, drop me a line. (But don’t send me any small-molecule companies that call themselves biopharmas!?That’s how I?got into this mess!)

—Gil Y. Roth, Editor

Top 10 Biopharmaceutical Companies
01 Amgen $14,311
02 Genentech $9,443
03 Novo Nordisk $7,696
04 Merck Serono $6,111
05 Baxter BioScience $4,649
06 Biogen Idec $3,063
07 Genzyme* $2,764
08 CSL Ltd.* $2,327
09 Allergan* $1,212
10 Elan* $446

Based on 2007 biopharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.

* PDF profiles only available for companies 7-10

Contributors


Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
  评论这张
 
阅读(310)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018